I-Hoffmann-La Roche Limited (i-Roche Canada) iyavuya ukwazisa ukuba ngoJanuwari 14, 2022, i-Health Canada igunyazise i-TECENTRIQ^® (atezolizumab) njengonyango lwe-monotherapy kunyango lwe-adjuvant emva kokuhlinzwa ngokupheleleyo kwaye akukho nkqubela emva kwe-platinam-based adjuvant chemotherapy kwizigulana zabantu abadala abanenqanaba le-II ukuya kwe-IIA * non-small cell lung cancer (NSCLC) enethumba elibonisa iPD-L1 ku≥ 50% iiseli ithumba (TCs).

I-TECENTRIQ luhlobo lonyango lwe-immunotherapy yomhlaza. I-Immunotherapy inokusebenza ngokunceda amajoni omzimba ukulwa neeseli ezinomhlaza. I-TECENTRIQ isebenza ngokuncamathisela kwiprotheyini ethile emzimbeni wakho ebizwa ngokuba yiProgrammed Death Ligand-1, okanye “PD-L1”. Le proteni yenza ukuba amajoni omzimba akho angasebenzi kakuhle. Ngokuncamathela kwiprotheyini, i-TECENTRIQ inceda amajoni akho omzimba ukuba alwe nomhlaza wakho kwaye inokuvuselela impendulo yokulwa nethumba.

"Umthwalo womhlaza wemiphunga ubalulekile kwaye unyango olutsha kulo naliphi na inqanaba lubalulekile ukubonelela ngeendlela ezininzi," kusho uShem Singh, uMlawuli oyiNtloko weLung Cancer Canada. Ngale mvume, abantu baseCanada abahlala ne-NSCLC ngoku banenye inketho xa kufikwa ekulawuleni esi sifo kwasekuqaleni kwaye banokuphucula umgangatho wobomi.

Ulwamkelo lusekwe kwidatha evela kuphononongo lweSigaba sesi-III se-IMpower010 ngokuthelekisa i-TECENTRIQ kukhathalelo olululo lwenkxaso (BSC) emva kwe-adjuvant cisplatin-based chemotherapy kwizigulana ezinomhlaza wemiphunga ongengowomncinci omncinci. Kulo pho nonongo, uphuculo olunentsingiselo yeklinikhi ekusindeni okungenasifo (DFS) kwingalo ye-TECENTRIQ iboniswe xa kuthelekiswa nengalo ye-BSC kwizigulane ezine-PD-L1 TC ≥ 50% isigaba se-II ukuya kwi-III.

I-TECENTRIQ inezibonakaliso ezilithoba ezivunyiweyo ngoku eCanada, ezimbini zazo ezivunyiweyo ngeemeko (NOC / c). Kunyango lwe-adjuvant ye-NSCLC yokuqala, i-TECENTRIQ ifumaneka kwiinketho ezintathu ze-dosing, inikezela ukuguquguquka kokukhetha ulawulo rhoqo kwiiveki ezimbini, ezintathu okanye ezine.

"Ukufakwa kwonyango olutsha kwizigulane zomhlaza wemiphunga ye-cell non-incinci ziindaba ezamkelekileyo," utsho uPeter Glazier, iSekela likaMongameli weLung Health Foundation. “Kuninzi lwabaguli abanomhlaza wemiphunga, inkqubela phambili kunyango incinci. Njengombutho ogxile ekujonganeni nezikhewu kuthintelo, ukuxilongwa, kunye nokhathalelo lwesifo semiphunga eCanada, siyaluxhasa kakhulu ukhetho olutsha lonyango lwabantu baseCanada abaphila nomhlaza wemiphunga. “

Umhlaza wemiphunga unokwahlulwa ngokubanzi ube ziindidi ezimbini eziphambili: iseli engeyincinci (NSCLC) kunye nomhlaza wemiphunga omncinci weseli (SCLC), malunga neepesenti ezingama-88 zeemeko zomhlaza wemiphunga eCanada (ngaphandle kweQuebec) yiNSCLC. Umhlaza wemiphunga ukwahlelwa ngokwamanqanaba, njengenqanaba I ukuya ku-IV, ngokusekelwe kubungakanani besifo emzimbeni ngexesha lokuxilongwa.

"Njengenkampani yezisombululo zezempilo, siyavuya ukubonelela ngokhetho olutsha lonyango kubantu baseCanada abaphila nomhlaza wemiphunga ongeyena omncinci," kusho uLoredana Regep, iSekela likaMongameli, iMicimbi yezoNyango kunye noLawulo, uHoffmann-La Roche Limited. "Olu kwamkelwa lwamva nje lunika oogqirha ithuba elongezelelweyo lokunyanga umhlaza wemiphunga emva kweminyaka engaphezu kweshumi kunye nenkqubela phambili yonyango olulinganiselweyo kwesi simo."

INTO ONOKUYITHATHA KWELI NQAKU:

As an organization focused on addressing the gaps in the prevention, diagnosis, and care of lung disease in Canada, we are very supportive of a new treatment option for Canadians living with lung cancer.
In this study, a clinically meaningful improvement in disease-free survival (DFS) in the TECENTRIQ arm was shown compared to the BSC arm in patients with PD-L1 TC ≥ 50% stage II to IIIA.
Lung cancer is also classified in stages, as stage I through IV, based on the extent of disease in the body at the time of diagnosis.